

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kenneth Brasel et al.

Serial No.: 10/643,384

Group Art Unit No.: 1644

Filed: August 19, 2003

Examiner: P. Gambel

For: USE OF FLT3-LIGAND IN THE TREATMENT OF INFECTION

Docket No.: 2836-US-DIV4

Confirmation No.: 4836

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form. In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications, or other information listed in this information disclosure statement are not required to be provided and are not enclosed as they were previously cited in prior application Serial No. 11/510,651 filed August 28, 2006.

Applicants make no determination of relevancy with respect to the reference(s) submitted herewith and request the Examiner to make an independent determination of the relevance and/or materiality of the reference(s). Applicant(s) request(s) consideration of this information and passage of the application to issue.

Please charge Deposit Account No. 09-0089 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 09-0089.

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, Washington 98119-3105
Phone: 206-265-7000

Respectfully submitted:


James E. Klaniacki
Registration No. 38,207

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence, and any other referenced document, is being electronically filed with the United States Patent and Trademark Office on the date indicated below.

Signed: 
Nanci M. Kertson

Date: Mar 3, 2009